• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    716.68 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    42 43 Next >
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
    Via Benzinga
    Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
    Via Benzinga
    Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
    The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
    Via Investor's Business Daily
    Exposures Product Safety
    Stock-Split Watch: Are These 2 Top Growth Stocks Next?
    Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
    Via The Motley Fool
    Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
    Via Benzinga
    3 Biotech Stocks to Buy for the Next Bull Run: March 2024
    These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
    Via InvestorPlace
    Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
    Via Investor Brand Network
    Regeneron Pharmaceuticals Unusual Options Activity For March 20
    Via Benzinga
    Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
    Via Benzinga
    FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
    The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data... 
    Via Benzinga
    Exposures Product Safety
    Regeneron Provides Update on Biologics License Application for Odronextamab
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
    The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. 
    Via InvestorPlace
    The 3 Most Undervalued Biotech Stocks to Buy in March 2024
    These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
    Via InvestorPlace
    Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
    Via Benzinga
    The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
    Via Benzinga
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
    $250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
    Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    2 No-Brainer Biotech Stocks to Buy Right Now
    These stocks are used to beating the market. 
    Via The Motley Fool
    Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
    Good news could be in store for all three of these drugmakers. 
    Via The Motley Fool
    Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
    Via Benzinga
    2 Biotech Stocks to Buy Hand Over Fist in March
    These stocks are worth buying in most months of the year. 
    Via The Motley Fool
    EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
    Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
    Via InvestorPlace
    Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
    Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
    Via Benzinga
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
    Via Benzinga
    Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
    Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
    Via Investor's Business Daily
    Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
    MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
    Via Talk Markets
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    42 43 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.